ECSP22041860A - Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso - Google Patents

Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso

Info

Publication number
ECSP22041860A
ECSP22041860A ECSENADI202241860A ECDI202241860A ECSP22041860A EC SP22041860 A ECSP22041860 A EC SP22041860A EC SENADI202241860 A ECSENADI202241860 A EC SENADI202241860A EC DI202241860 A ECDI202241860 A EC DI202241860A EC SP22041860 A ECSP22041860 A EC SP22041860A
Authority
EC
Ecuador
Prior art keywords
generation
methods
fever virus
yellow fever
virus antibodies
Prior art date
Application number
ECSENADI202241860A
Other languages
English (en)
Inventor
Anna Wec
Laura Walker
Original Assignee
Mabloc Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mabloc Llc filed Critical Mabloc Llc
Publication of ECSP22041860A publication Critical patent/ECSP22041860A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan anticuerpos y fragmentos de unión al antígeno de los mismos específicos para la proteína E de YFV y con potencia neutralizante contra YFV. Estos anticuerpos y fragmentos de unión al antígeno son útiles en el tratamiento de YFV.
ECSENADI202241860A 2019-11-25 2022-05-25 Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso ECSP22041860A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962940049P 2019-11-25 2019-11-25

Publications (1)

Publication Number Publication Date
ECSP22041860A true ECSP22041860A (es) 2022-09-30

Family

ID=74046131

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202241860A ECSP22041860A (es) 2019-11-25 2022-05-25 Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso

Country Status (14)

Country Link
US (3) US11479598B2 (es)
EP (1) EP4065601A1 (es)
JP (2) JP2023503347A (es)
KR (1) KR20220111289A (es)
CN (1) CN114867744B (es)
AU (1) AU2020394408A1 (es)
BR (1) BR112022010179A2 (es)
CA (1) CA3162718A1 (es)
CO (1) CO2022006909A2 (es)
EC (1) ECSP22041860A (es)
IL (1) IL293282A (es)
PE (1) PE20221865A1 (es)
WO (1) WO2021108448A1 (es)
ZA (1) ZA202205927B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021108448A1 (en) 2019-11-25 2021-06-03 Mabloc, Llc Anti-yellow fever virus antibodies, and methods of their generation and use
CN113683690B (zh) * 2021-08-19 2023-05-23 中国科学院微生物研究所 针对黄热病毒ns1蛋白的抗体及其应用
JP2024534892A (ja) * 2021-09-02 2024-09-26 メモリアル スローン ケタリング キャンサー センター 抗ｄｌｌ３抗体及びその使用
WO2023039437A1 (en) * 2021-09-07 2023-03-16 Mabloc, Llc Anti-sars-cov-2 antibody compositions and uses thereof
WO2024039298A1 (en) * 2022-08-17 2024-02-22 Agency For Science, Technology And Research Anti-yellow fever virus antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
PT2387583T (pt) 2009-01-14 2018-12-24 Ablynx Nv Administração pulmonar de domínios de variável única de imunoglobulina e construtos dos mesmos
PT2438087T (pt) 2009-06-05 2017-08-04 Ablynx Nv Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratório
CN106589116B (zh) * 2016-12-06 2020-01-03 中国科学院微生物研究所 一种黄病毒人源单克隆抗体及应用
CN110343174B (zh) * 2018-04-04 2021-05-04 中国科学院微生物研究所 一种高亲和力的黄热病毒人源单克隆抗体及其应用
CN113429479B (zh) * 2018-04-04 2023-03-10 中国科学院微生物研究所 一种高灵敏度的黄热病毒人源单克隆抗体及其应用
CN110343173B (zh) * 2018-04-04 2021-05-04 中国科学院微生物研究所 一种高功能活性的黄热病毒人源单克隆抗体及其应用
JP2021520854A (ja) * 2018-04-11 2021-08-26 タイチャン ピーティーイー．リミテッドＴｙｃｈａｎ Ｐｔｅ．Ｌｔｄ． 黄熱を処置するための方法および組成物
WO2021108448A1 (en) 2019-11-25 2021-06-03 Mabloc, Llc Anti-yellow fever virus antibodies, and methods of their generation and use

Also Published As

Publication number Publication date
AU2020394408A1 (en) 2022-06-09
PE20221865A1 (es) 2022-12-02
US20240218054A1 (en) 2024-07-04
EP4065601A1 (en) 2022-10-05
CN114867744B (zh) 2025-07-25
US20210253675A1 (en) 2021-08-19
IL293282A (en) 2022-07-01
JP2023503347A (ja) 2023-01-27
US20230203135A1 (en) 2023-06-29
JP7732118B2 (ja) 2025-09-01
CN114867744A (zh) 2022-08-05
KR20220111289A (ko) 2022-08-09
WO2021108448A1 (en) 2021-06-03
ZA202205927B (en) 2023-11-29
CO2022006909A2 (es) 2022-08-19
US11479598B2 (en) 2022-10-25
US12110319B2 (en) 2024-10-08
JP2025121907A (ja) 2025-08-20
CA3162718A1 (en) 2021-06-03
BR112022010179A2 (pt) 2022-08-30

Similar Documents

Publication Publication Date Title
CO2022006909A2 (es) Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso
JOP20210071A1 (ar) أجسام مضادة مثبّتة trem2
PH12020550650A1 (en) Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
CO2019012210A2 (es) Anticuerpos anti-trem2 y métodos para utilizarlos
UY40829A (es) Anticuerpos anti-phf-tau y sus usos
MX2021013355A (es) Composiciones de proteínas de fusión quiméricas modificadas y métodos de uso de las mismas.
CO2018003852A2 (es) Proteínas de unión a antigeno que activan el receptor de leptina
EA202091888A1 (ru) Вариабельные домены антител, нацеленные на рецептор nkg2d
MX2020000342A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos.
CO2022009737A2 (es) Anticuerpos anti-ly6g6d y métodos de uso
MX2022003517A (es) Anticuerpos anti-pd l1 y conjugados de anticuerpo-farmaco.
CR20180142A (es) ANTICUERPOS ANTI-FAP Y MÉTODOS DE USO(Divisional Exp: 2013-0038)
BR112021015477A2 (pt) Anticorpos anti-cd228 e conjugados anticorpo-fármaco
MX2024010593A (es) Anticuerpos 3e10 humanizados, variantes y fragmento de unión al antígeno de los mismos
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
WO2020036646A3 (en) Cancer neoantigens and their utilities in cancer vaccines and tcr-based cancer immunotherapy
UY37752A (es) Proteínas de unión al antígeno anti-jagged1
PE20171734A1 (es) Anticuerpos monoclonales especificos del antigeno m del virus metapneumovirus humano (hmpv) y su uso en un metodo de diagnostico
CL2019002642A1 (es) Anticuerpos de hantavirus andes y métodos de uso de los mismos.
AR133072A2 (es) Anticuerpos aislados o fragmentos aislados de unión a antígeno de los mismos que se unen al receptor de leptina humana (lepr) y activan la señalización lepr
AR115992A2 (es) Proteínas de unión a antígeno que activan el receptor de leptina
AR121129A1 (es) Anticuerpos anti-e-selectina, composiciones y métodos de uso
EA202092941A1 (ru) Конъюгаты камптотецина
WO2021016534A3 (en) Antigenic polypeptides and methods of use thereof